trial

Optimization of Treatment and Management of Schizophrenia in Europe

NCTId NCT01248195
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 479 (actual)
Sponsored by Rene Kahn
Primary completion 2016-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
479 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-05
Primary completion
2016-04
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
AmisulprideOlanzapineClozapinePsychosocial intervention

Sponsors

Rene KahnLead Sponsor
King's College LondonCollaborator
Technical University of MunichCollaborator
University of ManchesterCollaborator
Ludwig-Maximilians - University of MunichCollaborator

Investigators

1
René Kahn, Prof. Dr.Principal Investigator

Sites

26 total
Melbourne, AustraliaInnsbruck, AustriaLeuven, BelgiumSofia, BulgariaPrague, CzechiaHradec Králové, CzechiaGlostrup Municipality, DenmarkCréteil, FranceHalle, GermanyMannheim, GermanyMünchen, GermanyMünchen, Germany

Facts & assertions

4 sourced
Enrollment
479
Phase
PHASE4
Primary Completion Date
2016-04
Status
COMPLETED
relationships
The graph out of here
drug
Amisulpride
drug
Olanzapine
drug
Clozapine
drug
Psychosocial intervention
drug
lead_sponsor
Rene Kahn
company
collaborator
King's College London
company
Technical University of Munich
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
René Kahn, Prof. Dr.
person